BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17307058)

  • 1. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
    Uwaifo GI; Ratner RE
    Am J Cardiol; 2007 Feb; 99(4A):51B-67B. PubMed ID: 17307058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
    Harrigan RA; Nathan MS; Beattie P
    Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
    Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
    Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic treatment of diabetes].
    De Montigny P; Clerc C; Descarpentries C
    Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinically important effects of oral antidiabetic drug interactions].
    Drzewoski J; Kopff B
    Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral hypoglycemic agents on platelet function.
    Papazafiropoulou A; Papanas N; Pappas S; Maltezos E; Mikhailidis DP
    J Diabetes Complications; 2015 Aug; 29(6):846-51. PubMed ID: 26026848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hypoglycemic agents and heart.
    Manoria P; Manoria P
    Indian Heart J; 2007; 59(3):266-72. PubMed ID: 19124937
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes medications and body weight.
    Mitri J; Hamdy O
    Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral agents for type II diabetes. Taking a more aggressive approach to therapy.
    Hollander PA
    Postgrad Med; 1995 Dec; 98(6):110-1, 115-6, 119-21, passim. PubMed ID: 7501573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update on new oral treatment for diabetes].
    Awad J; Schindel B; Schindel Y
    Harefuah; 2001 Jan; 140(1):36-9. PubMed ID: 11242897
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cardiovascular effects of oral hypoglycemie drugs].
    Herrmann BL; Erbel R; Janssen OE; Mann K
    Herz; 2004 Aug; 29(5):510-8. PubMed ID: 15340737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.